Moreover, the presence of the whole tumor during neoadjuvant PD-1 inhibitor combined with chemotherapy allows a triggering of a broader T cell response due to a larger repertoire of tumor antigen exposure, then establish systemic immune surveillance and destruction of micrometastases (38, 39). This evidence concerns the gene PDCD1 and neoplasm.